ArticleEuropean radiology2012
Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours.
Article in European radiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic performance of [European radiology · 2019Pooled it
- Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2013Pooled it
- Meta-analysis of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastases.PloS one · 2012Pooled it
- Review
- Comparative study of total-body PET and PET/MR in the diagnosis of liver metastases.Frontiers in oncology · 2025Article
- Article
- Comparison ofCurrent oncology (Toronto, Ont.) · 2024Article
- PET/MRI imaging in neuroendocrine neoplasm.Abdominal radiology (New York) · 2023Review
- Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Detection of distant metastases and distant second primary cancers in head and neck squamous cell carcinoma: comparison of [Insights into imaging · 2022Article
- Quantitative diffusion MRI of the abdomen and pelvis.Medical physics · 2022Article
- Review
- Added value of [European radiology · 2021Article
- Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities.Reviews in endocrine & metabolic disorders · 2021Review
- High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- The impact of 18F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract.BMC medical imaging · 2020Article
- ShouldWorld journal of surgery · 2020Article
- PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype?Clinical and translational imaging · 2019Article
- [Neuroendocrine tumors of the stomach, duodenum and pancreas : Value of (hybrid) radiological diagnostics].Der Radiologe · 2019Review
- PreoperativeWorld journal of surgery · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study was performed to assess the role of retrospective PET-MRI fusion with Ga-68-DOTA(0)-Phe(1)-Tyr(3)-octreotide (Ga-68-DOTATOC) PET and Gd-EOB-DTPA MRI in the detection of hepatic metastases from neuroendocrine tumours (NET).
methodsTwenty-two consecutive patients with suspected liver metastases from histopathologically proven NET were examined with Gd-EOB-DTPA MRI and multiphase contrast-enhanced Ga-68-DOTATOC PET/CT. PET and MRI images were retrospectively fused using commercially available software. Two physicians experienced in nuclear medicine and radiology analysed the images to assess diagnostic confidence and characterise liver lesions.
resultsA total of 181 lesions were detected. PET-MRI showed a sensitivity of 91.2% (significantly superior to PET/CT; P < 0.05) and a specificity of 95.6% (significantly superior to MRI; P < 0.05). PET/CT had a sensitivity of 73.5% and a specificity of 88.2%. MRI had a sensitivity of 87.6% and a specificity of 86.8%. The area under the curve was 0.98 for PET-MRI, 0.96 for MRI, and 0.89 for PET/CT (P < 0.05).
conclusionsRetrospectively fused PET-MRI was superior to multiphase contrast-enhanced Ga-68-DOTATOC PET/CT and Gd-EOB-DTPA MRI in the detection of NET liver metastases. It was more sensitive than PET/CT and more specific than MRI. Fused PET-MRI therefore seems well suited for surgical and interventional treatment planning of NET liver metastases. KEY POINTS: • Ga-68-DOTATOC PET-Gd-EOB-DTPA MRI fusion can improve imaging of liver metastases of neuroendocrine tumours. • This technique appears more sensitive than PET/CT for staging NET hepatic metastases. • Ga-68-DOTATOC PET-Gd-EOB-DTPA MRI fusion is more specific than MRI alone.
Indexed as
Identifiers
21904802What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.